Bidirectional Link ID'd for Autoimmune Disease, Perinatal Depression
19 Jan 2024
Clinical Result
FRIDAY, Jan. 19, 2024 -- There is a bidirectional association between autoimmune disease (AD) and perinatal depression (PND), according to a study published online Jan. 9 in Molecular Psychiatry.
Emma Bränn, from the Karolinska Institutet in Stockholm, and colleagues examined the bidirectional association between PND and AD using nationwide Swedish population and health registers. A total of 55,299 incident PND cases were included, as well as their unaffected full sisters, and 10 unaffected matched women per PND case. Forty-one subtypes of AD diagnoses were identified from the registers.
The researchers found that women with an AD had an increased risk for subsequent PND (odds ratio, 1.30), and women exposed to PND had an increased risk for subsequent AD (odds ratio, 1.30). Comparing exposed women with their unaffected sisters yielded comparable associations (nested case-control odds ratio, 1.3; matched cohort hazard ratio, 1.3); associations were also comparable when studying antepartum and postpartum depression. Women without psychiatric comorbidities had a more pronounced bidirectional association (nested case-control odds ratio, 1.5; matched cohort hazard ratio, 1.4), with the strongest association seen for multiple sclerosis (nested case-control odds ratio, 2.0; matched cohort hazard ratio, 1.8).
"These findings have implications for research on biological mechanisms, and for health care professionals who need to be alert to the risk of PND in women with AD, and vice versa," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.